FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer. PMID 42103553 · Lung Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study. PMID 42098463 · Int J Clin Oncol · 2026-Jul The study meets the criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it fails the core requirement for a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The reported endpoints are pharmacokinetic, pathological complete response, and safety. Therefore, it is not eligible for inclusion in this cohort. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials. PMID 42095986 · Gastric Cancer · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Integrated perioperative host-response optimization improves functional recovery and survival after ultra-low anterior resection: A randomized controlled trial. PMID 42092267 · Surgery · 2026-Jul The trial is a randomized, oncology-focused study with time-to-event endpoints, but the intervention is a non-drug perioperative optimization program, which violates the drug-intervention requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE. PMID 42084697 · Am J Clin Dermatol · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis. PMID 42084657 · Adv Ther · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comment on "Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial". PMID 42070935 · Clin Ther · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Letter to the Editor Regarding "Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial". PMID 42070934 · Clin Ther · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Sitagliptin, Metformin and Glimepiride Fixed-Dose Combination Compared to Co-Administration of Metformin and High-Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double-Blind, Double-Dummy, Phase 3 Clinical Study. PMID 42070788 · Diabetes Obes Metab · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes. PMID 42070786 · Diabetes Obes Metab · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Lifitegrast ophthalmic solution 5.0% (KH732) for dry eye disease: A randomized, multicenter, double-masked, vehicle-controlled phase 3 trial. PMID 42069335 · Ocul Surf · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Factors associated with arm swelling in patients undergoing surgery and radiotherapy for breast cancer within the FAST-Forward trial nodal sub-study. PMID 42067068 · Radiother Oncol · 2026-Jul The study meets criteria for oncology, human, randomized, and Phase III, but is excluded because it lacks a drug-containing intervention (intervention is radiotherapy) and lacks a time-to-event efficacy endpoint (endpoint is patient-reported arm swelling, a safety/toxicity outcome). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL). PMID 42059487 · Palliat Med · 2026-Jul The study is a randomized Phase III oncology trial with a drug intervention, but its primary and reported endpoints are quality of life, body weight, and cost parameters. There is no signal of a time-to-event efficacy endpoint (e.g., OS, PFS, HR, Kaplan-Meier) in the title, abstract, or metadata. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis. PMID 42055319 · Kidney Int · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590. PMID 42047965 · Esophagus · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 3 Panel · risk unclear |
| Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis. PMID 42046405 · Diabetes Obes Metab · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. PMID 42044466 · J Clin Oncol · 2026-Jul This record describes a secondary, correlative analysis of circulating tumor DNA (ctDNA) from the TRANSFORM trial, not the primary efficacy report. While the trial itself is likely a randomized Phase III study (as it compares a new therapy to standard of care in a second-line setting), the provided text is a biomarker-focused analysis ('correlative circulating tumor DNA analyses'). The eligibility criteria require the 'original formal-result report' of the primary/key secondary time-to-event endpoint. This report's primary purpose is to present ctDNA biomarker associations, making it a secondary or correlative analysis report, not the primary efficacy report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials. PMID 42036875 · Clin Exp Allergy · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The ALLAN trial: impact of early home-based palliative care on emergency care and hospitalisation in advanced gastrointestinal cancer patients. PMID 42032200 · Br J Cancer · 2026-Jul The trial is a randomized controlled trial in advanced gastrointestinal cancer patients with a drug-containing intervention (palliative chemotherapy), but it does not meet the key eligibility criteria. The primary endpoint is quality of life, and the presented results focus on secondary outcomes (healthcare utilization, place of death). There is no primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) reported; the only time-related outcome ('time from last chemotherapy to death') is not presented with KM data or HR and is described as not significantly different. The report is not a Phase III/IIIb or definitive Phase II/III trial (phase is not established in the provided metadata). It is a secondary analysis of a trial focused on palliative care integration, not a definitive drug efficacy report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis. PMID 42027097 · Diabetes Obes Metab · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma. PMID 42025759 · Ann Oncol · 2026-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Laparoscopic extrahepatic Glissonian versus hilar dissection approach for major hepatectomy in patients with HCC: a randomized controlled trial. PMID 42020776 · Br J Cancer · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. PMID 42017294 · Diabetes Obes Metab · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial. PMID 42014556 · Br J Cancer · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer. PMID 42005715 · Clin Transl Radiat Oncol · 2026-Jul 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914). PMID 41999978 · Ann Oncol · 2026-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. PMID 41999030 · J Hepatobiliary Pancreat Sci · 2026-Jul The record describes an ancillary analysis of the JASPAC 01 trial, not the original formal result report of the Phase III trial. The analysis evaluates the timing of adjuvant chemotherapy initiation (early, standard, delayed) rather than the trial's primary comparison of S-1 vs. gemcitabine. The phase is not explicitly confirmed in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efgartigimod in Sjögren's disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO). PMID 41997805 · Ann Rheum Dis · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results. PMID 41992416 · HIV Med · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7. PMID 41975042 · Br J Cancer · 2026-Jul While the record describes a Phase III randomized trial (DREAMM-7) with a drug intervention, the abstract focuses on pharmacometric exposure-response modeling for response (e.g., ≥VGPR) and safety endpoints. There is no mention of a time-to-event efficacy endpoint (e.g., OS, PFS) or associated Kaplan-Meier/HR results. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Minimizing Early-Onset Lymphedema Following Groin Dissection in Metastatic Melanoma. PMID 41973292 · Ann Surg Oncol · 2026-Jul The study is a randomized oncology trial but does not meet key eligibility criteria: it lacks a drug-containing intervention (uses compression garments and lymphatic drainage), does not report a time-to-event efficacy endpoint as a primary/key secondary (primary endpoint is 24-month incidence, a proportion), and the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT). PMID 41967704 · Ann Allergy Asthma Immunol · 2026-Jul 方案论文未报告临床试验结果。 |
H
L
|
旧查询独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Structural and construct validity assessment of the schizophrenia cognition rating scale (SCoRS) using data from three international phase 3 randomized controlled trials (CONNEX programme). PMID 41967302 · Schizophr Res · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of vitamin D status and supplementation on exploratory inflammatory biomarkers in preschoolers with asthma. PMID 41966354 · Ann Allergy Asthma Immunol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Preoperative Biliary Drainage with Metal Stent Versus Early Surgery in Patients with Pancreatic Cancer: A Randomized Clinical Trial. PMID 41951900 · Ann Surg Oncol · 2026-Jul 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial. PMID 41949794 · Ophthalmic Physiol Opt · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial. PMID 41943179 · Am J Hematol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluating quality of life in thoracic malignancy trials: A scoping review on ESMO-MCBS quality of life checklist adherence and concordance with progression-free and overall survival. PMID 41937091 · Crit Rev Oncol Hematol · 2026-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis. PMID 41937031 · J Am Acad Dermatol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Motivation-informed digital reminders were no more effective than standard reminders for trial task completion in a randomized Study Within A Trial (SWAT). PMID 41933841 · J Clin Epidemiol · 2026-Jul The record is an original randomized trial on melanoma (oncology), but it is a 'Study Within A Trial' (SWAT) evaluating the effectiveness of digital reminder systems for trial task completion. It does not involve a drug intervention, nor does it report a time-to-event efficacy endpoint (OS, PFS, etc.) from a Phase III/IIIb or Phase II/III randomized trial of a cancer drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial. PMID 41933275 · Aliment Pharmacol Ther · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Systematic statistical analysis of change in SEIzure interVAL with diazepam nasal spray supports this novel clinical endpoint for immediate-use seizure medication. PMID 41919765 · Epilepsia · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma: a Japanese subgroup analysis of RATIONALE-306 with ≥ 3 years of follow-up. PMID 41917381 · Esophagus · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders. PMID 41913506 · J Pediatr Gastroenterol Nutr · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial. PMID 41902639 · Epilepsia · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial. PMID 41895581 · Chest · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. PMID 41894094 · Int J Hematol · 2026-Jul The record is a primary result report of a Phase III randomized trial in human oncology with a drug intervention and a time-to-event efficacy endpoint (PFS with HR). All required criteria are explicitly established in the title, abstract, and metadata. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 1 Panel · risk visible |
| A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome. PMID 41891667 · Epilepsia · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials. PMID 41887529 · JHEP Rep · 2026-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: Results from a 6-month open-label extension study. PMID 41880832 · Eur Neuropsychopharmacol · 2026-Jul 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |